Study of the Medullary Microenvironment in Acute Childhood Leukemia

Recruiting now · Not applicable

Conditions studied: Acute Lymphoid Leukemia, Acute Myeloid Leukemia in Children

In brief

Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.

Key facts

Study ID

NCT05792007

Run by

University Hospital, Tours

People needed

40

Starts

2023-10-26

Expected to finish

2028-10-24

Last updated by the study team

2025-11-24

Who can join

Age: 1 and older, up to 15. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• for patients with AL:
• Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
• Not having received prior hematological treatment
• Aged 1 to 15 years old
• Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
• Affiliated patient or beneficiary of a social security scheme.
• Control group patients:
• Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis).
• Aged between 1 and 15 years old.
• Having no pathology of hematological origin.
• Not having received any treatment that could interfere with the functioning of the bone marrow.
• Whose 2 parents or the holder of parental authority have signed a consent enlightened.
• Affiliated patient or beneficiary of a social security scheme.

You may not qualify if…

• for patients with AL:
• Patient under 1 year old and over 15 years old.
• Contraindication to myelogram.
• Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
• Patients with relapsed acute lymphoblastic or myeloblastic leukemia.
• Having received prior hematological treatments.
• Parents with physical or mental condition not allowing to understand the informed consent.
• Control group patients
• Patient under 1 year old and over 15 years old.
• Having an underlying haematological pathology.
• Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
• Having received prior hematological treatments.
• Parents with physical or mental condition not allowing to understand informed consent.

Where it is running

• Service d'onco-hématologie pédiatrique -CHRU Tours — Tours, France (enrolling)
• Service de chirurgie orthopédique pédiatrique -CHRU TOURS — Tours, France (enrolling)
• Service d'hématologie biologique-CHRU TOURS — Tours, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.